Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years

Abstract

PDxBr is a digital BC test combining automated AI-BC prognostic grade with clinical-pathologic features to predict the risk of early-stage BC recurrence. With future validation studies, we anticipate the PDxBr model will enrich current gene expression assays and enhance treatment decision-making.